Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/8297
Full metadata record
DC FieldValueLanguage
dc.rights.licenseopenAccess-
dc.contributor.authorJovanovic, Marina-
dc.contributor.authorGajovic, Nevena-
dc.contributor.authorLukic, Miodrag-
dc.contributor.authorPopovic, Ana-
dc.contributor.authorJovanovic, Ivan-
dc.date.accessioned2020-09-19T15:20:26Z-
dc.date.available2020-09-19T15:20:26Z-
dc.date.issued2019-
dc.identifier.issn1820-8665-
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/8297-
dc.description.abstract© 2019, University of Kragujevac, Faculty of Science. All rights reserved. When it comes to tumor immunology, understanding of molecular pathways is rather important. During oncogenesis, many molecules should be taken in consideration altogether in context of a single malignancy. It is of a great significance to determine whether these molecules act synergistically or contrary, whether to understand a malignant disease more thoroughly, or even more important, to reveal new approaches of therapy. In this review, we discuss whether and how IL-33/ST2 and PD-1/PDL axis involve in antitumor immunity.-
dc.rightsinfo:eu-repo/semantics/openAccess-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.sourceSerbian Journal of Experimental and Clinical Research-
dc.titleSynergism of pdl/pd1 and il33/st2 axis in tumor immunology-
dc.typearticle-
dc.identifier.doi10.2478/SJECr-2018-0033-
dc.identifier.scopus2-s2.0-85078858835-
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)

417

Downloads(s)

21

Files in This Item:
File Description SizeFormat 
10.2478-SJECr-2018-0033.pdf381.06 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons